Zura Bio Completes Enrollment In Phase 2 TibuSHIELD Trial of Tibulizumab in Adults With HS

Zura Bio

Zura Bio

ZURA

0.00
  • Tibulizumab is the first and only bispecific antibody targeting both BAFF and IL-17 in clinical development
  • TibuSHIELD has completed enrollment, exceeding enrollment target with 247 participants randomized in HS; topline data expected Q4 2026
  • TibuSURE has exceeded the 80 participant enrollment target in SSc and remains on track to complete enrollment in early July; topline data expected H1 2027
  • Zura plans to initiate a Phase 2 study for tibulizumab in a third immune-mediated indication by year end 2026
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.